来源：钛媒体 图 片由AI生成 2025年的合成生物产业，在喧嚣中沉淀，在挑战中前行。 市场规模的持续扩容，印证着这一赛道的巨大产业价值——全球合成生物学市场规模预计在今年达到245.8亿美元，2027年将增至387亿美元，2032年有望冲 破千亿美元大关；中国市场的增长曲线更显陡峭，从2016年的9亿美元跃升至2021年的64亿美元，今年预计突破70亿美元，未来仍将保持高速增长态势。 与传统吃药、打针的治疗逻辑不同，CAR-T堪称"细胞级精准武器"的医疗革命，通过提取患者自身免疫细胞，在实验室中改造训练后再回输体内作战，正是 合成生物学的崛起及其工程化思维和可控基因线路的引入，才为CAR-T疗法带来了创新的改造方向。若把CAR-T比作抗癌士兵，合成生物学就是给士兵升级 装备和战术，让它们能精准感知、应对肿瘤微环境的挑战。世界经济论坛《2025年十大新兴技术》报告将"工程化活体疗法"纳入新一代健康生物技术领域， 这项技术通过合成生物学与精准医疗的深度融合，利用人工设计的有益细菌在人体内执行治疗功能，既能降低长期医疗成本，又能显著改善疗效。 镜头拉远，作为一门多学科交叉的底层技术，合成生物学打破传统学科界限，融 ...

【SynBioCon】 获 悉， 近日， 山东大学微生物改造技术全国重点实验室祁庆生团队 在《 Metabolic Engineering 》上发表题为" Engineered Non-Canonical Reductive TCA Pathway Drives High-Yield Succinic Acid Biosynthesis in Yarrowia lipolytica "的研究论文。博士研究生 陶慧琳为论文第一作者，祁庆生教授和崔志勇副研究员为通讯作者。山东大学微生物改造技术全国重点实验室为第一完成单位和通讯作者单位。 C4-二羧酸是一类具有应用价值的化合物，广泛应用于医药、化工、食品等领域。其中，丁二酸作为多种高价值化学品的平台化合物，可以合成1,4 - 丁二醇、四氢呋喃、聚丁二酸丁二醇酯等产品，在化工以及塑料降解领域具有重要价值。解酯耶氏酵母凭借优异的耐酸性以及对低成本原料的兼容性， 成为丁二酸生物合成的潜力宿主。还原TCA（rTCA）途径由于合成路径短、理论转化率高是目前C4-二羧酸合成的主要途径。但酵母不存在天然的 rTCA途径，异源引入后胞质内NADH不足以满足rTCA途径合成丁二酸所 ...

Investment Rating - The investment rating for the company is "Hold" [5] Core Views - The company reported a revenue of 2.2 billion yuan for the first three quarters of 2025, representing a year-on-year increase of 43%. However, the net profit attributable to the parent company was 170 million yuan, a decrease of 1.3% year-on-year [1] - Despite weak price performance of main products, the increase in sales volume has contributed to revenue growth. The average price of valine was 14 yuan/kg, down 4.5% year-on-year, while tryptophan and arginine saw price declines of 29% and 25% respectively [2] - The company is optimizing product resource allocation and enhancing sustainable profitability through increased R&D investment in new products, including biobased materials [2][3] - The establishment of an AI digital laboratory aims to integrate AI technology into synthetic biology and company management, enhancing operational efficiency [3] - The company plans to issue overseas shares and list on the Hong Kong Stock Exchange to support its globalization strategy and improve capital structure [3] Financial Summary - For 2025, the company expects net profits of 230 million yuan, 310 million yuan, and 360 million yuan for the years 2025, 2026, and 2027 respectively, with adjustments made due to declining prices of some main products [3] - The projected revenue for 2025 is 3.16 billion yuan, with a growth rate of 44.98% [4] - The company’s EBITDA for 2025 is estimated at 495.79 million yuan, with a P/E ratio of 42.63 [4][10] Product and Market Strategy - The company is advancing projects in biobased materials and has initiated technical upgrades to existing production facilities to allow flexible production of various products [2] - The R&D expenditure for the first three quarters of 2025 was 110 million yuan, reflecting a year-on-year increase of 17.58% [3]

Core Viewpoint - The article emphasizes the economic feasibility of converting non-grain biomass waste, such as straw, into high-value products through comprehensive innovation across the entire supply chain [2][4]. Group 1: Research and Development - Professor Jin Mingjie’s team at Nanjing University of Science and Technology has addressed key challenges in the biorefining process of lignocellulosic biomass, including high raw material collection and transportation costs, stringent pretreatment conditions, toxic byproducts, low bioconversion efficiency, and difficulties in lignin degradation [2]. - A novel pretreatment technology and biorefining system have been developed to solve critical issues in the biorefining process [2]. - The team has developed a high-solid enzymatic hydrolysis technology that achieves a fermentable sugar concentration exceeding 200 g/L, allowing for efficient fermentation of hydrolysate into products like cellulose ethanol, lactic acid, succinic acid, citric acid, and lipids without the need for washing or detoxification [2]. Group 2: Lignin Utilization - The research includes the analysis of lignin biodegradation pathways and the discovery of new lignin-degrading enzymes, employing a "biological funnel" strategy to construct multiple engineered strains for the efficient conversion of lignin into high-value products such as muconic acid and gallic acid [2]. Group 3: Company Formation and Impact - In 2024, Professor Jin Mingjie founded Suzhou Limi Biotechnology Co., Ltd. in Suzhou High-tech Zone, which has developed globally leading complete technologies with independent intellectual property rights, breaking through the industrialization bottleneck of converting non-grain biomass waste into high-value biochemical products [4]. - The establishment of this company is considered epoch-making in the field of biomass utilization [4]. Group 4: Industry Engagement - Professor Jin Mingjie is scheduled to present a report titled "Biorefining of Lignocellulosic Biomass Based on 'Sugar' Platform" at the 2025 Non-Grain Biomass High-Value Utilization Forum (NFUCon 2025) in Hangzhou, Zhejiang, from January 27 to 29, 2025, inviting industry participation for exchange [5].

Investment Rating - The investment rating for the company is "Buy" with expectations of a stock price increase of over 15% relative to the industry index in the next six months [5][20]. Core Viewpoints - The company is advancing its "Bio + AI" strategy to build a multi-dimensional product system, which includes amino acids, vitamins, and bio-based new material monomers. This diversification is expected to enhance profitability and growth potential as new products are gradually launched and technical upgrades are completed [9][10][11]. - The company reported a revenue of 1.489 billion yuan in the first half of 2025, a year-on-year increase of 46.54%, while the net profit attributable to the parent company was 115 million yuan, a decrease of 23.26% year-on-year [1][2]. Financial Performance Summary - **Revenue Growth**: The projected revenue for 2025 is 2.617 billion yuan, with a year-on-year growth rate of 20.1%. The revenue is expected to continue growing to 3.098 billion yuan in 2026 and 3.591 billion yuan in 2027 [1][11]. - **Net Profit**: The net profit attributable to the parent company is projected to be 240 million yuan in 2025, recovering to 298 million yuan in 2026 and 381 million yuan in 2027, with corresponding growth rates of 26.6%, 24.3%, and 27.6% respectively [1][11]. - **Profitability Ratios**: The return on equity (ROE) is expected to improve from 7.2% in 2024 to 12.2% in 2027, indicating a recovery in profitability [1][11]. - **Earnings Per Share (EPS)**: The EPS is projected to be 0.96 yuan in 2025, increasing to 1.19 yuan in 2026 and 1.52 yuan in 2027 [1][11]. Cash Flow and Financial Health - The net cash flow from operating activities in the first half of 2025 was 75 million yuan, a decrease of 9.93% year-on-year. The net cash flow from investing activities was -261 million yuan, an increase of 40.91% year-on-year, primarily due to reduced cash payments for fixed assets and intangible assets [3]. - The company’s cash and cash equivalents at the end of the period were 379 million yuan, a decrease of 3.63% year-on-year [3]. Market Conditions and Product Pricing - The overall gross profit margin for the first half of 2025 was 24.11%, a decline of 7.49 percentage points compared to the same period in 2024. This decline is attributed to rising costs of amino acids and vitamins, as well as a decrease in the prices of certain products [2][4]. - The price of L-alanine dropped approximately 42.86% from early 2025 to the end of June 2025, which has exerted pressure on the company's performance [4]. Strategic Initiatives - The company is focusing on enhancing its research and development capabilities, particularly in the integration of AI technology within its operations. This initiative aims to improve production efficiency and product quality, thereby supporting sustainable growth [10].

Core Viewpoint - The company has announced a delay in the "Malic Acid Co-production Tryptophan Project," extending the expected operational date from 2025 to October 2026 due to project implementation and investment progress considerations [5][6][7]. Fundraising and Investment Project Overview - The company raised approximately RMB 699.99 million through a private placement of 21,122,510 shares at RMB 33.14 per share, with net proceeds after expenses amounting to RMB 683.81 million [1][2]. - The total planned investment for the projects was adjusted from RMB 700 million to RMB 683.81 million, with specific allocations for projects detailed in a table [2][3]. Fund Usage and Project Status - As of June 30, 2025, the company has fully utilized the raised funds for the "Succinic Acid Co-production Valine/Inositol Project" and the "Malic Acid Co-production Tryptophan Project," with investment ratios exceeding 100% for both projects [4]. - The company has established a special account for the management of the raised funds, ensuring compliance with regulatory requirements [2][3]. Delay Reasons and Impact - The delay in the "Malic Acid Co-production Tryptophan Project" is based on the need for technical upgrades to production equipment and alignment with market demand [5][6]. - The company asserts that the delay will not affect the project's investment direction, implementation entity, or method, and it does not pose any risk to shareholder interests [6][7]. Approval and Compliance - The board of directors and the supervisory board have approved the delay, and the decision complies with relevant regulations and internal governance [7][8].

Core Viewpoint - The company has decided to postpone the completion date of the "Apple Acid Co-production Tryptophan Project" from 2025 to October 2026 due to actual construction progress and investment considerations [5][6][7]. Fundraising and Investment Project Overview - The company has successfully raised a net amount of RMB 683.81 million after deducting issuance costs of RMB 16.19 million, with all funds received by October 21, 2024 [1][2]. - The adjusted fundraising allocation for investment projects totals RMB 683.81 million, down from an initial plan of RMB 700 million [2][3]. Fund Usage and Project Status - As of June 30, 2025, the company has fully utilized the raised funds for the "Apple Acid Co-production Tryptophan Project" and the "Succinic Acid Co-production Valine/Inositol Project," with investment ratios exceeding 100% for both projects [5][6]. - The company has established a special account for the management of raised funds, ensuring compliance with regulatory requirements [2][3]. Delay Details - The postponement of the "Apple Acid Co-production Tryptophan Project" is based on market demand and technical upgrades to production equipment, with no changes to the project's investment direction or implementation [6][7]. - The company has confirmed that the delay will not adversely affect the normal operation of the company or the interests of shareholders, particularly minority investors [8]. Approval and Oversight - The decision to postpone the project has been approved by the company's board and supervisory committee, adhering to necessary regulatory procedures [8][9]. - The sponsor institution has conducted a thorough review and supports the decision, confirming that it aligns with relevant laws and regulations [8][9].

Investment Rating - The report maintains a "Buy" rating for the company [9][12]. Core Views - The company reported a revenue of 1.49 billion yuan for the first half of 2025, representing a year-on-year increase of 46.5%. However, the net profit attributable to shareholders decreased by 23.3% to 110 million yuan [2][6]. - In Q2 2025, the company achieved a revenue of 800 million yuan, which is a 55.6% increase year-on-year and a 16.7% increase quarter-on-quarter. The net profit for the same quarter was 60 million yuan, reflecting a year-on-year increase of 1.0% and a quarter-on-quarter increase of 24.9% [2][6]. - The company is focusing on optimizing product resource allocation and enhancing profitability through investments in bio-based new materials, particularly 1,3-propanediol [12][12]. - The company is advancing its projects systematically, with ongoing developments in various production facilities aimed at increasing output for products like tryptophan and L-valine [12][12]. - The company is leveraging AI technology in its research and development processes to enhance operational efficiency and product development [12][12]. - The company is recognized as a leading player in the bio-manufacturing sector, with high technical barriers for its products, and future growth in new product volumes is anticipated [12][12]. Financial Summary - The company expects net profits attributable to shareholders to reach 280 million yuan, 380 million yuan, and 640 million yuan for the years 2025, 2026, and 2027, respectively [12][12]. - The gross margin for Q2 2025 was reported at 23.9%, a decrease of 5.7 percentage points year-on-year and a decrease of 0.4 percentage points quarter-on-quarter [12][12].

Core Viewpoint - Hua Heng Biological achieved significant revenue growth in the first half of 2025, driven by increased product sales and strong performance in various segments [1][2]. Financial Performance - In the first half of 2025, the company reported revenue of 1.489 billion yuan, a year-on-year increase of 46.54% [1]. - The net profit attributable to shareholders was 115 million yuan, with the same amount for the net profit after deducting non-recurring gains and losses [1]. - In Q2, the net profit reached 63.8 million yuan, a quarter-on-quarter increase of 24.86%, while the net profit after deducting non-recurring gains and losses was 64.1 million yuan, up 26.32% [1]. - The net cash flow from operating activities was 74.7 million yuan, reflecting a significant quarter-on-quarter increase of 275.36% [1]. Research and Development - Hua Heng Biological maintained high investment in R&D, with expenses reaching 68.7 million yuan, an increase of 8.40% year-on-year, accounting for 4.61% of total revenue [1]. - The company achieved notable R&D outcomes, including 6 new invention patents and 3 utility model patents, bringing the total to 84 invention patents and 80 utility model patents [1]. - The establishment of an AI digital laboratory aims to integrate proprietary strain platforms and production capabilities, enhancing the conversion of cutting-edge technology into marketable products [1]. Production and Flexibility - The company enhanced its flexible manufacturing capabilities to meet market demand for products like L-valine and myo-inositol through technical upgrades of existing facilities [2]. - The production setup allows for interchangeable production of various products, improving asset utilization and resilience against market fluctuations [2]. - Key products include amino acids, vitamins, and bio-based new material monomers, applicable across multiple industries such as animal nutrition and functional foods [2]. Market Opportunities - The demand for amino acids continues to grow due to policies promoting precise nutrition and reduced protein feed, leading to a revenue increase of 42.29% in the amino acid segment, totaling 1.057 billion yuan [2]. - The bio-based new materials, including 1,3-propanediol and succinic acid, are gaining investor attention due to their applications in pharmaceuticals and sustainable production methods [3]. - The company is actively investing in the industrialization of these bio-based materials, collaborating with institutions to promote market adoption [3]. International Expansion - Hua Heng Biological's overseas business has been expanding, with foreign assets reaching 277 million yuan, accounting for 5.23% of total assets [4]. - The company has established stable partnerships with global giants like BASF and Ajinomoto, while also maintaining long-term collaborations with domestic firms [4].

Core Viewpoint - The company is actively implementing its "Quality Improvement and Efficiency Enhancement" action plan for 2025, focusing on enhancing operational management, core competitiveness, and profitability in the biotechnology sector [1][2][3] Group 1: Business Development and Financial Performance - The company achieved total operating revenue of 1,489.16 million yuan, representing a year-on-year growth of 46.54%, with net profit attributable to shareholders reaching 114.89 million yuan, showing a quarter-on-quarter increase [1] - The company is focusing on biomanufacturing and applying successful production experiences to accelerate the industrialization of high-quality technological achievements, thereby enriching its product variety and enhancing the value of its industrial chain [1][2] Group 2: Product and Resource Optimization - The company is increasing R&D investment in new products, establishing a multi-dimensional product system that includes amino acids, vitamins, and bio-based new material monomers [2] - The company is enhancing the production capacity of L-valine and inositol by optimizing existing facilities and implementing flexible production technologies [2] Group 3: Internationalization and Brand Influence - The company is deepening its international development strategy, collaborating with Fortune 500 companies and industry leaders to expand into international markets and enhance its service capabilities [2][3] Group 4: R&D and Innovation - The company is committed to increasing R&D investment, with R&D expenses amounting to 68.67 million yuan, an increase of 8.40% year-on-year, and has a total of 512 patent applications [3][4] - The company emphasizes the integration of independent R&D and industry-academia collaboration to maintain technological leadership in the industry [4] Group 5: Corporate Governance and Investor Relations - The company has established a governance structure that ensures clear responsibilities and coordinated operations among its various governing bodies [4] - The company prioritizes high-quality information disclosure and investor communication, utilizing multiple channels to engage with investors and respond to their concerns [5] Group 6: Sustainable Development and ESG Commitment - The company adheres to a sustainable development strategy, focusing on green manufacturing and low-carbon initiatives, and has published its ESG report to showcase its commitment to environmental and social governance [6] - The company aims to optimize resource utilization and reduce reliance on traditional energy sources while enhancing operational efficiency [6] Group 7: Future Outlook and Continuous Improvement - The company will continue to evaluate the execution of its action plan and expand its product matrix to enhance core competitiveness and profitability [6][7]